Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 71 of 6351
-
Bladder cancer trial pits radiotherapy against standard immunotherapy
Disease control Not yet recruitingIn the UK 20,000 people develop urothelial bladder cancer each year with 75-80% having Non-Muscle Invasive Bladder Cancer (NMIBC). The current standard of care for patients with High Risk-NMIBC (HR-NMIBC) is either surgery to remove the tumour (transurethral resection of bladder …
Phase 3 • Sponsor: The Christie NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill plus immunotherapy shows promise for liver cancer
Disease control Not yet recruitingThe goal of this clinical trial is to determine if TPST-1120 in combination with atezolizumab and bevacizumab helps patients to live longer compared to atezolizumab and bevacizumab alone (the standard of care treatment) in adult patients with hepatocellular carcinoma that cannot …
Phase 3 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:20 UTC
-
New CAR t-cell therapy takes on hard-to-treat leukemia
Disease control Not yet recruitingThe purpose of this adaptive Phase 1/2 study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antileukemic activity of CCTx-001 in adult patients with r/r Acute Myeloid Leukemia (AML). CCTx-001 targets IL-1RAP, which is specifically expressed in leukemic cells.…
Phase 1/2 • Sponsor: Advesya SAS • Aim: Disease control
Last updated Jun 26, 2026 18:29 UTC
-
AI could spot liver cancer types and predict survival without needle biopsy
Diagnosis OngoingThis study aims to develop a comprehensive artificial intelligence model system integrating preoperative multimodal data (CT/MRI imaging, clinical laboratory data, and radiology report text) to achieve two core objectives. First, to develop a multimodal fusion diagnostic model fo…
Sponsor: Guangxi Medical University • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New pill could keep lung cancer away after surgery
Disease control Recruiting nowTo assess the efficacy and safety of sunvozertinib versus placebo as adjuvant therapy in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins) or P-loop and αC-helix compression (PA…
Phase 3 • Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New trial aims to halve deaths in newborns with severe heart disease
Disease control Recruiting nowThere remains controversy regarding the optimal timing of surgical treatment for neonatal CCHD (Complex Congenital Heart Disease). Based on the established national multi-center database for surgical treatment of congenital heart disease and the prenatal-postnatal integrated diag…
Sponsor: Central China Fuwai Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take on philadelphia Chromosome-Positive leukemia
Disease control Recruiting nowA Multicenter Study of CD19 CAR-T Cells in the Treatment of Adult Patients With Primary Ph Chromosome Positive Acute Lymphoblastic Leukemia
Phase 2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
CAR-T cells take on stubborn leukemia after transplant in new trial
Disease control Recruiting nowThis prospective, open-label randomized controlled trial compares CD19 CAR-T therapy with chemotherapy plus donor lymphocyte infusion (DLI) in 70 patients with Ph-negative B-cell acute lymphoblastic leukemia (B-ALL) who exhibited minimal residual disease (MRD) positivity (≥0.1% C…
Phase 3 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for tough lung cancer: targeted drug ZL-1310 enters final testing
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Phase 3 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New stroke drug could give patients up to 24 hours to seek treatment
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy of recombinant human tissue-type plasminogen activator variant (rhTNK-tPA) (0.25 mg/kg, maximum dose 25 mg) compared with placebo in patients with acute …
Phase 3 • Sponsor: CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Engineered immune cells take on tough T-Cell cancers in new trial
Disease control Not yet recruitingTo Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL/ALL.
Phase 2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Immune cells from your own tumor could fight advanced melanoma
Disease control OngoingThis is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma
Phase 2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for men with Hard-to-Treat prostate cancer: drug combo trial launches
Disease control Recruiting nowThe primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo aims to fight advanced kidney cancer
Disease control Recruiting nowResearchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compar…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
Disease control Recruiting nowThe subjects of this study are patients with unresectable stage III non-small cell lung cancer (NSCLC) who have EGFR mutations.
Phase 2 • Sponsor: Peng Zhang • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo aims to beat tough leukemia
Disease control Recruiting nowThe purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.
Phase 3 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Gene therapy offers hope for kids with rare brain disease
Disease control OngoingRGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system. This study is a safety, efficacy, and pharmacodynamic dose ranging study to determine whether RGX-121 is safe, effective and well-tolera…
Phase 3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for tough pancreatic cancer: targeted drug combo enters final testing phase
Disease control Recruiting nowThis study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation. Patients were randomized 1:1 to receive either the experimental regimen HRS-4642 plus AG or the control regimen AG alone.
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for kids with aggressive nerve cancer: immune-boosting combo trial opens
Disease control Recruiting nowNeuroblastoma (NB) is a malignant neoplasm of the sympathetic nervous system, occurring in 1 in 8,000 live births, accounting for 6-10% of all childhood malignant neoplasms and responsible for 12-15% of mortality -, making it the most common and life-threatening extracranial tumo…
Phase 3 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Promising lyme vaccine moves to final testing phase
Vaccine OngoingThe purpose of this study is to learn about the safety and effects of the Lyme disease vaccine (called VLA15) when given at different time points. This study is seeking participants who: * are generally healthy and between 18 and 44 years of age, * have never had a vaccine for …
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC